ClinicalTrials.gg
CompletedNCT00801723Updated Aug 31, 2020Results posted

(CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.

A Phase 3 interventional study of Budesonide MMX 6 mg Tablet and Placebo Tablet in Ulcerative Colitis, sponsored by Bausch Health Americas, Inc.. Completed at 58 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-08-31.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 18 studies in Colitis, Ulcerative by Bausch Health Companies Inc. — 2 open to participants now, 2 under way, none of them phase 3. Colitis, Ulcerative · Bausch Health Companies Inc..

Enrollment
13th of 18
123 · median 273
Started
2008
with 2 others
Phase 3
14 of 18
none open now
Registered
9th of 18
by date

Among the 18 studies in Colitis, Ulcerative by Bausch Health Companies Inc., this one is the 13th largest by enrollment, is one of 3 that started in 2008, is one of 14 in phase 3, and was the 9th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

2 of the 18 studies in Colitis, Ulcerative by Bausch Health Companies Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Colitis, Ulcerative by Bausch Health Companies Inc., or all of them as a file.
02

Study summary

Randomized, double-blind, comparative study versus placebo performed in patients from studies CB-01-02/01 (NCT00679432), CB-01-02/02 (NCT00679380), or CB-01-02/06 (NCT01100112) who achieved ulcerative colitis disease activity index (UCDAI) remission after 8 weeks of treatment.

Patients in remission at the End of Study visit will be given the opportunity to enter the 12-month Maintenance Phase study outlined in this protocol (CB-01-02/04). The End of Study visit in studies 01, 02, and 06 will be set as the Visit 1 (Day 0) of this study. There will be no interruption of study treatment between the parent studies and this study.

It is planned that approximately 150 patients will be enrolled in the study. Patients will be randomly assigned to two groups to receive either budesonide MMX 6 mg or placebo irrespective of the treatment assigned in studies 01, 02, or 06. Treatments will be administered once a day after breakfast for a maximum of 12 months or up to the occurrence of the first clinical relapse, where clinical relapse is defined as combined recurrence of rectal bleeding and stool frequency ≥ 1-2 stools/day above normal for the patient (score ≥ 1 in both UCDAI items).

During the study, patients will be assessed for safety and efficacy at Visit 1 and after 1, 3, 6, 9, and 12 months of treatment.

Patients will be contacted by telephone on a monthly basis for safety assessment. In case of occurrence of symptoms suggestive of clinical relapse, patients will attend an unscheduled visit at any time during the study.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • Ulcerative Colitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients fulfilling the following criteria are eligible for participation in the study:

    • Male and female patients, 18-75 years old, who are able to understand and voluntarily provide written .
    • Patients in UCDAI remission defined as a UCDAI score ≤ 1 point with a score of 0 for rectal bleeding and stool frequency, and a ≥ 1 point reduction from baseline in the endoscopy score without any sign of mucosal friability (score 0 for mucosal appearance).
    • Patients who have completed all End of Study assessments for the CB-01-02/01, CB-01-02/02 and CB-01-02/06 studies.
    • Females of must have had a serum pregnancy test performed at the End of Study visit of the parent studies and must use an acceptable method throughout the study treatment period.

Exclusion criteria

Exclusion Criteria:

  • Patients who meet any of the following criteria at screening visit are to be excluded from study participation:

    • Subjects who have withdrawn from studies CB-01-02/01, CB 01 02/02 or CB-01-02/06.
    • Subjects who did not achieve induction of remission according to the primary endpoint definition in studies CB-01-02/01, CB 01 02/02 or CB-01-02/06 (i.e. clinical remission defined as a UCDAI score ≤ 1 point with a score of 0 for rectal bleeding and stool frequency, and ≥ 1 point reduction from baseline in the endoscopy score without any sign of mucosal friability [score 0 for mucosal appearance]).
    • Subjects with bone density lower than normal by age and sex (T-score lower than -1) as assessed via dual energy X-ray absorptiometry (DXA) scans.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    1: Budesonide MMX® 6 mg

    One Budesonide-MMX® 6 mg tablet self-administered by the patients with a glass of water, in the morning after breakfast.

    Drug: Budesonide MMX 6 mg Tablet

  • Placebo comparator
    2: Placebo

    One placebo tablet self-administered by the patients with a glass of water, in the morning after breakfast.

    Drug: Placebo Tablet

Interventions

  • DrugBudesonide MMX 6 mg Tablet

    Budesonide MMX 6 mg Tablet once daily.

  • DrugPlacebo Tablet

    Placebo Tablet once daily.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Clinical Remission

    Clinical remission was defined as the combined absence of recurrence of rectal bleeding and absence of increased stool frequency.

    Time frame: 1, 3, 6, 9, and 12 months

Secondary outcomes

  1. Percentage of Participants With Clinical Relapse

    Clinical relapse was defined as the recurrence of rectal bleeding and/or an abnormal stool frequency \[≥ 1-2 stools/day above normal for the participant. Clinical remission/relapse status was based on participant diary entries prior to each scheduled visit.

    Time frame: 12 months

  2. Percentage of Participants With Endoscopic Relapse

    Endoscopic relapse was defined as an increase of ≥ 2 points in the Endoscopic Index score from the value calculated at baseline. The score is comprised of four components (granulated scattering reflected light, vascular pattern, vulnerability of mucosa, and mucosal damage). Scores range from 0 to 12, and higher scores indicate more severe (worse) endoscopic findings.

    Time frame: 12 months

07

Results

Posted Aug 17, 2020

Participant flow

Participant flow — Overall Study
Milestone2: Placebo1: Budesonide MMX® 6 mg
Started6162
Completed2527
Not completed3635

Outcome measures

PrimaryPercentage of Participants Achieving Clinical Remission

Clinical remission was defined as the combined absence of recurrence of rectal bleeding and absence of increased stool frequency.

Time frame:
1, 3, 6, 9, and 12 months
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Remission
percentage of participants2: Placebo1: Budesonide MMX® 6 mg
1 month76.788.2
3 months92.096.8
6 months76.280.0
9 months86.795.0
12 months84.693.3
SecondaryPercentage of Participants With Clinical Relapse

Clinical relapse was defined as the recurrence of rectal bleeding and/or an abnormal stool frequency \[≥ 1-2 stools/day above normal for the participant. Clinical remission/relapse status was based on participant diary entries prior to each scheduled visit.

Time frame:
12 months
Reported as:
Count of participants · Participants
Percentage of Participants With Clinical Relapse
Participants2: Placebo1: Budesonide MMX® 6 mg
Percentage of Participants With Clinical Relapse1912
SecondaryPercentage of Participants With Endoscopic Relapse

Endoscopic relapse was defined as an increase of ≥ 2 points in the Endoscopic Index score from the value calculated at baseline. The score is comprised of four components (granulated scattering reflected light, vascular pattern, vulnerability of mucosa, and mucosal damage). Scores range from 0 to 12, and higher scores indicate more severe (worse) endoscopic findings.

Time frame:
12 months
Reported as:
Count of participants · Participants
Percentage of Participants With Endoscopic Relapse
Participants2: Placebo1: Budesonide MMX® 6 mg
Percentage of Participants With Endoscopic Relapse1627

Adverse events

Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
2: Placebo—1/61 (1.6%)30/61 (49.2%)
1: Budesonide MMX® 6 mg—1/62 (1.6%)34/62 (54.8%)
Most frequent serious events
Most frequent serious events
Event2: Placebo1: Budesonide MMX® 6 mg
Lobar pneumoniaInfections and infestations1/610/62
HypertensionVascular disorders0/611/62
Most frequent other events
Most frequent other events
Event2: Placebo1: Budesonide MMX® 6 mg
Colitis ulcerativeGastrointestinal disorders16/6111/62
Abdominal painGastrointestinal disorders5/616/62
OsteopeniaMusculoskeletal and connective tissue disorders5/611/62
HeadacheNervous system disorders2/614/62
Frequent bowel movementsGastrointestinal disorders1/614/62
HaematocheziaBlood and lymphatic system disorders1/614/62
ConstipationGastrointestinal disorders0/614/62

Baseline characteristics

Age, Continuous
Age, Continuous(years)2: Placebo1: Budesonide MMX® 6 mgTotal
Mean42.0 ± 11.7742.9 ± 12.6542.5 ± 12.21
Sex: Female, Male
Sex: Female, Male(Participants)2: Placebo1: Budesonide MMX® 6 mgTotal
Female282654
Male333669
08

Study locations

58 sites
  • Santarus Clinical Investigational Site 5051
    Huntsville, Alabama 35801, United States
  • Santarus Clinical Investigational Site 5088
    Tucson, Arizona 85712, United States
  • Santarus Clinical Investigational Site 5044
    Anaheim, California 92801, United States
  • Santarus Clinical Investigational Site 5087
    Lakewood, California 90712, United States
  • Santarus Clinical Investigational Site 5033
    Los Angeles, California 90045, United States
  • Santarus Clinical Investigational Site 5070
    Palm Springs, California 92262, United States
  • Santarus Clinical Investigational Site 5067
    San Diego, California 92101, United States
  • Santarus Clinical Investigational Site 5064
    Lakewood, Colorado 80215, United States
  • Santarus Clinical Investigational Site 5089
    Boynton Beach, Florida 33426, United States
  • Santarus Clinical Investigational Site 5041
    Hollywood, Florida 33021, United States
  • Santarus Clinical Investigational Site 5055
    New Smyrna Beach, Florida 32168, United States
  • Santarus Clinical Investigational Site 5074
    Port Orange, Florida 32127, United States
  • Santarus Clinical Investigational Site 5032
    Tampa, Florida 33607, United States
  • Santarus Clinical Investigational Site 5009
    Tampa, Florida 33613, United States
  • Santarus Clinical Investigational Site 5047
    Winter Park, Florida 32789, United States
  • Santarus Clinical Investigational Site 5003
    Zephyrhills, Florida 33542, United States
  • Santarus Clinical Investigational Site 5016
    Atlanta, Georgia 30312, United States
  • Santarus Clinical Investigational Site 5056
    Columbus, Georgia 31904, United States
  • Santarus Clinical Investigational Site 5068
    Evanston, Illinois 60201, United States
  • Santarus Clinical Investigational Site 5008
    Metairie, Louisiana 70006, United States
  • Santarus Clinical Investigational Site 5090
    Annapolis, Maryland 21401, United States
  • Santarus Clinical Investigational Site 5025
    Baltimore, Maryland 21229, United States
  • Santarus Clinical Investigational Site 5092
    Hollywood, Maryland 20636, United States
  • Santarus Clinical Investigational Site 5077
    Prince Frederick, Maryland 20678, United States
  • Santarus Clinical Investigational Site 5010
    Chesterfield, Michigan 48047, United States
  • Santarus Clinical Investigational Site 5006
    Troy, Michigan 48098, United States
  • Santarus Clinical Investigational Site 5004
    Wyoming, Michigan 49519, United States
  • Santarus Clinical Investigational Site 5005
    Marlton, New Jersey 08053, United States
  • Santarus Clinical Investigational Site 5011
    Great Neck, New York 11021, United States
  • Santarus Clinical Investigational Site 5101
    New York, New York 10016, United States
  • Santarus Clinical Investigational Site 5020
    Pittsford, New York 14534, United States
  • Santarus Clinical Investigational Site 5096
    Fayetteville, North Carolina 28304, United States
  • Santarus Clinical Investigational Site 5058
    Huntersville, North Carolina 28078, United States
  • Santarus Clinical Investigational Site 5091
    New Bern, North Carolina 28562, United States
  • Santarus Clinical Investigational Site 5045
    Cincinnati, Ohio 45219, United States
  • Santarus Clinical Investigational Site 5078
    Dayton, Ohio 45440, United States
  • Santarus Clinical Investigational Site 5001
    Yukon, Oklahoma 73099, United States
  • Santarus Clinical Investigational Site 5066
    Duncansville, Pennsylvania 16635, United States
  • Santarus Clinical Investigational Site 5065
    Pottstown, Pennsylvania 19464, United States
  • Santarus Clinical Investigational Site 5035
    Sayre, Pennsylvania 18840, United States
  • Santarus Clinical Investigational Site 5021
    Austin, Texas 78745, United States
  • Santarus Clinical Investigational Site 5076
    Houston, Texas 77034, United States
  • Santarus Clinical Investigational Site 5019
    Houston, Texas 77090, United States
  • Santarus Clinical Investigational Site 5036
    Houston, Texas 77090, United States
  • Santarus Clinical Investigational Site 5063
    Irving, Texas 75061, United States
  • Santarus Clinical Investigational Site 5072
    Kingwood, Texas 77339, United States
  • Santarus Clinical Investigational Site 5054
    La Porte, Texas 77571, United States
  • Santarus Clinical Investigational Site 5030
    Lewisville, Texas 75057, United States
  • Santarus Clinical Investigational Site 5093
    Plano, Texas 75075, United States
  • Santarus Clinical Investigational Site 5100
    San Antonio, Texas 78229, United States
  • Santarus Clinical Investigational Site 5079
    San Antonio, Texas 78258, United States
  • Santarus Clinical Investigational Site 5015
    Salt Lake City, Utah 84107, United States
  • Santarus Clinical Investigational Site 5097
    Christiansburg, Virginia 24073, United States
  • Santarus Clinical Investigational Site 6014
    Vancouver, British Columbia V6Z 2K5, Canada
  • Santarus Clinical Investigational Site 6008
    Victoria, British Columbia V8R 1J8, Canada
  • Santarus Clinical Investigational Site 6004
    Richmond Hill, Ontario L4B 3P8, Canada
  • Santarus Clinical Investigational Site 6006
    Toronto, Ontario M3N 2V7, Canada
  • Santarus Clinical Investigational Site 6013
    Longueuil, Quebec J4N 1E1, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of May 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2020, 9 years 3 months after primary completion. A results delay was requested in Dec 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2008
First posted
Dec 3, 2008
Start
Dec 2008
Primary completionActual
May 2011
CompletionActual
Jun 2011
Results delay requested
Dec 1, 2011
Results first posted
Aug 17, 2020
Last update
Aug 31, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00801723
Responsible party
Sponsor
First posted
Dec 3, 2008
Start date
Dec 2008
Primary completion
May 2011
Completion
Jun 2011
Results posted
Aug 17, 2020
Last update
Aug 31, 2020

Study contacts

Bruce Eric Sands
principal investigator · Massachusetts General Hospital
Simon Travis
principal investigator · Oxford University Hospitals NHS Trust

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion